Research Library

What the research actually says

Each summary covers mechanism, key studies, and current regulatory status.

FDA approvedApproved outside U.S.InvestigationalPreclinical only

The best-studied compound in this library. FDA approved for type 2 diabetes (2022) and chronic weight management (2023).

Eli Lilly's investigational 'triple agonist.' Phase 2 results were striking, and the Phase 3 TRIUMPH program is underway.

Novo Nordisk's combination of an amylin analog with semaglutide (the active ingredient in Wegovy®).

Popular for tendon and gut healing. Rodent research is extensive, but well-controlled human trials don't exist yet.

Often stacked with BPC-157 (the so-called 'Wolverine stack'). Its parent protein has some human data. TB-500 itself has none.

Originally isolated from thymus tissue. It is approved in a number of countries outside the U.S. as an immune therapy.

Discovered in 1977 and studied for sleep. Human results have been small and inconsistent.

Binds to the inner membrane of mitochondria. Received FDA accelerated approval in 2025 for Barth syndrome, a rare genetic disease.

An 'exercise-mimetic' in mouse studies. Human research is at a very early stage.

A popular combination for raising growth hormone. Each peptide has limited human data, and the combination has none.

Cleared senescent ('zombie') cells in a notable 2017 mouse study. It has never been tested in humans.

Widely used in skincare. Topical evidence for skin firmness and repair is modest but real.